David Eiznhamer
Impact in
- Hematology top 10%
- Hematopoietic Stem Cell Transplantation
- Gastroenterology top 10%
- Gastroesophageal reflux and treatments
Papers in
- Hematology 11
- Hematopoietic Stem Cell Transplantation 8
- Chronic Myeloid Leukemia Treatments 3
- Co-authors
- Ze‐Qi XuAli KeshavarzianE W HolmesSherri YongMichael T. FlavinThomas SchnellMojtaba OlyaeeStephen J. Sontag
- Journals
- Blood (5 papers)Biology of Blood and Marrow Transplantation (3 papers)Molecular Microbiology (2 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
David Eiznhamer
28 papers receiving 649 citations
Peers
Comparison fields: 5 of 88
- Hematology 86
- Gastroenterology 34
- Toxicology 19
- Immunology 106
- Transplantation 12
Countries citing papers authored by David Eiznhamer
This map shows the geographic impact of David Eiznhamer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Eiznhamer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Eiznhamer more than expected).
Fields of papers citing papers by David Eiznhamer
This network shows the impact of papers produced by David Eiznhamer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Eiznhamer. The network helps show where David Eiznhamer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David Eiznhamer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 3 | |
| 2 | 2021 | 1 | |
| 3 | 2020 | 2 | |
| 4 | 2019 | 5 | |
| 5 | 2019 | 4 | |
| 6 | 2018 | 6 | |
| 7 | 2016 | 10 | |
| 8 | 2012 | 20 | |
| 9 | 2010 | 9 | |
| 10 | 2009 | 10 | |
| 11 | 2009 | 27 | |
| 12 | A Comparative Study of the Safety and Efficacy of Cethromycin (CER) to Clarithromycin (CLR) for the Treatment of Community Acquired Pneumonia (CAP) in Adults (CL05-001) | 2008 | 2 |
| 13 | A Thorough QT Study to Define the ECG Effects of Cethromycin (CER) Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (MFX) in Healthy Subjects (CL07-001) | 2008 | 2 |
| 14 | 2004 | 7 | |
| 15 | Betulinic acid: a promising anticancer candidate. | 2004 | 105 |
| 16 | 2001 | 21 | |
| 17 | 2001 | 71 | |
| 18 | 1998 | 77 | |
| 19 | 1996 | 8 | |
| 20 | 1995 | 91 |
About David Eiznhamer
David Eiznhamer is a scholar working on Hematology, Applied Microbiology and Biotechnology, Immunology, Toxicology and Genetics, having authored 29 papers that have together received 673 indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (8 papers), Acute Lymphoblastic Leukemia research (6 papers), Plant biochemistry and biosynthesis (5 papers), CAR-T cell therapy research (4 papers), Natural product bioactivities and synthesis (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Immune Response and Inflammation (3 papers). The work is most often cited by research in Hematology (86 citations), Gastroenterology (34 citations), Toxicology (19 citations), Immunology (106 citations) and Transplantation (12 citations). David Eiznhamer has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Ze‐Qi Xu, Ali Keshavarzian, E W Holmes, Sherri Yong, Michael T. Flavin, Thomas Schnell, Mojtaba Olyaee, Stephen J. Sontag, Sohrab Mobarhan and Shahriar Sedghi. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Molecular Microbiology, Bioorganic & Medicinal Chemistry Letters and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.